Residency · Residency · Internal Medicine

Type 2 Diabetes: Individualized Pharmacotherapy Beyond Metformin

Introduction

The management of type 2 diabetes has undergone a paradigm shift. While metformin remains a reasonable first-line agent, the 2022 ADA/EASD consensus and subsequent updates emphasize a cardiorenal-metabolic approach where agent selection is driven by comorbidities rather than glucose lowering alone. The emergence of GLP-1 receptor agonists and SGLT2 inhibitors with proven cardiovascular and renal benefits has fundamentally changed the treatment algorithm.

Glycemic Targets

• HbA1c < 7% for most non-pregnant adults (ADA standard target)
• HbA1c < 6.5% if achievable without significant hypoglycemia (select younger patients, short disease duration)
• HbA1c < 8% for elderly patients, limited life expectancy, extensive comorbidities, or high hypoglycemia risk
• Time in range (TIR): > 70% of time between 70-180 mg/dL on continuous glucose monitoring correlates with HbA1c < 7%

Metformin: The Traditional Foundation

• Mechanism: reduces hepatic glucose production, improves insulin sensitivity
• Benefits: low cost, weight neutral to modest weight loss, no hypoglycemia, extensive safety record
• Limitations: GI side effects (use extended-release to mitigate), contraindicated if eGFR < 30 mL/min, dose reduction at eGFR < 45
• Key shift: ADA 2023 guidelines state that SGLT2i or GLP-1 RA should be initiated for cardiorenal benefit independent of HbA1c and independent of metformin use

SGLT2 Inhibitors

Agents and Mechanism

• Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin
• Block sodium-glucose cotransporter 2 in the proximal tubule, causing glycosuria
• HbA1c reduction: 0.5-0.8%
• Weight loss: 2-3 kg; systolic BP reduction: 3-5 mmHg

Cardiovascular and Renal Benefits

• EMPA-REG OUTCOME: empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35%
• DAPA-HF / EMPEROR-Reduced: benefit in HFrEF regardless of diabetes status
• CREDENCE / DAPA-CKD: slowed CKD progression, reduced albuminuria
• Indications beyond glucose: HFrEF, HFpEF, CKD with albuminuria (now used in non-diabetic populations)

Adverse Effects and Precautions

• Genital mycotic infections (most common, 5-10%)
• Euglycemic diabetic ketoacidosis: rare; hold peri-operatively and during acute illness
• Volume depletion: caution in elderly, diuretic use
• Canagliflozin: historical signal for amputations and fractures (not confirmed with other agents)

GLP-1 Receptor Agonists

Agents and Mechanism

• Semaglutide (subcutaneous weekly, oral daily), liraglutide (daily), dulaglutide (weekly), tirzepatide (dual GIP/GLP-1 agonist, weekly)
• Enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, promote satiety
• HbA1c reduction: 1.0-2.0%; weight loss: 5-15% (tirzepatide up to 20%)

Landmark Trials

• SUSTAIN-6 / PIONEER-6: semaglutide reduced MACE
• LEADER: liraglutide reduced cardiovascular death by 22%
• SURPASS trials: tirzepatide achieved HbA1c < 5.7% in up to 50% of participants
• SELECT: semaglutide 2.4 mg reduced MACE by 20% in patients with obesity and established CVD without diabetes

Adverse Effects

• GI symptoms (nausea, vomiting, diarrhea): dose-escalate gradually to mitigate
• Pancreatitis: rare; avoid in patients with prior pancreatitis
• Thyroid C-cell tumors: signal in rodents; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
• Gallbladder disease: increased risk with rapid weight loss

Other Agents

DPP-4 Inhibitors

• Sitagliptin, linagliptin, saxagliptin, alogliptin
• Modest HbA1c reduction (0.5-0.7%), weight neutral, well-tolerated
• Cardiovascular safety trials showed neutrality (no benefit, no harm, except saxagliptin and HF risk)
• Role diminishing as GLP-1 RAs become more accessible

Thiazolidinediones

• Pioglitazone: improves insulin sensitivity, durable glucose lowering, NASH benefit (histologic improvement)
• Risks: weight gain, fluid retention, heart failure exacerbation, fractures, bladder cancer concern
• Consider in NASH with insulin resistance if no contraindications

Insulin

• Basal insulin (glargine, degludec): add when oral/injectable agents fail to achieve target
• Basal-bolus or premixed regimens: for advanced disease with significant beta-cell failure
• Degludec has lower hypoglycemia risk than glargine U100 (DEVOTE trial)
• Insulin + GLP-1 RA fixed-ratio combinations (iDegLira, iGlarLixi): simplify regimens, mitigate insulin-associated weight gain

The Modern Treatment Algorithm

1. Assess for ASCVD, heart failure, or CKD at diagnosis
2. If ASCVD or high CV risk: GLP-1 RA with proven benefit (semaglutide, liraglutide, dulaglutide)
3. If HF: SGLT2 inhibitor (empagliflozin, dapagliflozin)
4. If CKD with albuminuria: SGLT2 inhibitor (independent of glucose); consider adding finerenone (non-steroidal MRA)
5. If primary goal is weight management: tirzepatide or semaglutide
6. If cost is a major barrier: metformin + sulfonylurea or pioglitazone
7. Reassess HbA1c every 3 months; intensify therapy if above target

Key Clinical Pearls

• SGLT2 inhibitors and GLP-1 RAs should be prescribed for their cardiorenal benefits independent of HbA1c level
• Tirzepatide (dual GIP/GLP-1 agonist) produces the greatest HbA1c reduction and weight loss of any non-insulin agent
• Hold SGLT2 inhibitors 3-4 days before planned surgery to prevent euglycemic DKA
• Never combine a GLP-1 RA with a DPP-4 inhibitor (redundant mechanism; no added benefit)

References

1. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
4. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446.

Read this lecture as Markdown